Roche’s Elecsys preeclampsia test has demonstrated high prognostic value in the multicenter, prospective, double-blind, non-interventional PROGNOSIS study, which was conducted to predict the condition in pregnant women.
The new data was presented at the 20th World Congress on Controversies in Obstetrics, Gynecology & Infertility in Paris.
The Elecsys preeclampsia test has been developed to measure two proteins, soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF) in maternal blood.
The test result will now allow physicians to confidently predict the development of short-term preeclampsia in pregnant women, while focus on those patients at high risk of the disease.
Medical University Vienna, Department of Obstetrics and Gynecology professor Harald Zeisler said: "Results from the PROGNOSIS study mark a significant step forward in the prediction of preeclampsia.
"The Elecsys preeclampsia test allows physicians to predict the short term absence and manifestation of preeclampsia. Its application in clinical practice has the potential to reduce fetal and maternal morbidity and mortality as well as to avoid unnecessary hospitalizations."
Launched in 2010, the Elecsys preeclampsia test is available in all CE mark accepting countries in Europe, Latin America, Middle East, Africa and Asia. It is currently not available in the US and Japan.